1.
Society AC. Cancer Facts & Figures 2015. 2015.
2.
Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute 2012 December 23, 2015.
3.
Society AC. Melanoma Skin Cancer; 2015.
4.
Constantinou M. Melanoma Genomics and Immunotherapy. R I Med J (2013). 2015;98(11):31–4.
5.
Skin Cancer Prevention Progress Report 2016. Atlanta: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2016.
6.
Hong WK, Spitz MR, Lippman SM. Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J Clin Oncol. 2000;18(21 Suppl):9s–18s.
PubMed
7.
Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41(3):269–85.
CrossRefPubMed
8.
Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54(6):933–46 (quiz 47–50).
9.
Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18(1):43–9.
CrossRefPubMed
10.
Lotan R, Giotta G, Nork E, Nicolson GL. Characterization of the inhibitory effects of retinoids on the in vitro growth of two malignant murine melanomas. J Natl Cancer Inst. 1978;60(5):1035–41.
PubMed
11.
Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res. 1979;39(3):1014–9.
PubMed
12.
Levine N, Meyskens FL. Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet (London, England). 1980;2(8188):224–6.
13.
Meyskens FL Jr, Edwards L, Levine NS. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol. 1986;15(4 Pt 2):822–5.
CrossRefPubMed
14.
Edwards L, Jaffe P. The effect of topical tretinoin on dysplastic nevi. A preliminary trial. Arch Dermatol. 1990;126(4):494–9.
CrossRefPubMed
15.
Halpern AC, Schuchter LM, Elder DE, Dt Guerry, Elenitsas R, Trock B, et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol. 1994;12(5):1028–35.
PubMed
16.
Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S. Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res. 1998;8(6):539–48.
CrossRefPubMed
17.
Bettoli V, Zauli S, Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatol Treat. 2013;24(3):235–7.
CrossRef
18.
Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618–26.
CrossRefPubMed
19.
Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, et al. A phase 2 randomised controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016. doi:
10.1111/bjd.14662.
20.
Thompson BC, Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. Exp Dermatol. 2014;23(7):509–11.
CrossRefPubMed
21.
Horvath A, Alvarado F, Szocs J, de Alvardo ZN, Padilla G. Metabolic effects of calagualine, an antitumoral saponine of
Polypodium leucotomos. Nature. 1967;214(5094):1256–8.
CrossRefPubMed
22.
Murbach TS, Beres E, Vertesi A, Glavits R, Hirka G, Endres JR, et al. A comprehensive toxicological safety assessment of an aqueous extract of
Polypodium leucotomos (Fernblock((R))). Food Chem Toxicol. 2015;86:328–41.
CrossRefPubMed
23.
Nestor MS, Berman B, Swenson N. Safety and efficacy of oral
Polypodium leucotomos extract in healthy adult subjects. J Clin Aesthet Dermatol. 2015;8(2):19–23.
PubMedPubMedCentral
24.
Zattra E, Coleman C, Arad S, Helms E, Levine D, Bord E, et al.
Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol. 2009;175(5):1952–61.
CrossRefPubMedPubMedCentral
25.
Alcaraz MV, Pathak MA, Rius F, Kollias N, Gonzalez S. An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model. A pilot study. Photodermatol Photoimmunol Photomed. 1999;15(3–4):120–6.
26.
Gonzalez S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB. Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed. 1997;13(1–2):50–60.
27.
Middelkamp-Hup MA, Pathak MA, Parrado C, Goukassian D, Rius-Diaz F, Mihm MC, et al. Oral
Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol. 2004;51(6):910–8.
CrossRefPubMed
28.
Villa A, Viera MH, Amini S, Huo R, Perez O, Ruiz P, et al. Decrease of ultraviolet A light-induced “common deletion” in healthy volunteers after oral
Polypodium leucotomos extract supplement in a randomized clinical trial. J Am Acad Dermatol. 2010;62(3):511–3.
CrossRefPubMed
29.
Aguilera P, Carrera C, Puig-Butille JA, Badenas C, Lecha M, Gonzalez S, et al. Benefits of oral
Polypodium Leucotomos extract in MM high-risk patients. J Eur Acad Dermatol Venereol. 2013;27(9):1095–100.
CrossRefPubMed
30.
Premi S, Wallisch S, Mano CM, Weiner AB, Bacchiocchi A, Wakamatsu K, et al. Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science (New York, NY). 2015;347(6224):842–7.
31.
Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr. 2007;137(9):2098–105.
PubMed
32.
Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, et al. Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer (Oxford, England : 1990). 2010;46(18):3316–22.
33.
Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Philadelphia, Pa). 2012;5(2):164–78.
34.
Ye X, Fu J, Yang Y, Gao Y, Liu L, Chen S. Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One. 2013;8(7):e71522.
CrossRefPubMedPubMedCentral
35.
Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology. 2005;68(1):40–7.
CrossRefPubMed
36.
Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010;172(5):578–90.
CrossRefPubMedPubMedCentral
37.
Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf. 2009;18(4):276–83.
CrossRefPubMed
38.
Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4(1):31–8.
CrossRefPubMed
39.
Goodman JR, Grossman D. Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Philadelphia, Pa). 2014;7(6):557–64.
40.
Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011;131(7):1460–8.
CrossRefPubMed
41.
Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sorensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012;118(19):4768–76.
CrossRefPubMed
42.
Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer. 2011;105(3):452–9.
CrossRefPubMedPubMedCentral
43.
Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative. Cancer. 2013;119(8):1562–9.
CrossRefPubMed
44.
Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ Health Study. Cancer Causes Control. 2012;23(9):1451–61.
CrossRefPubMedPubMedCentral
45.
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55.
CrossRefPubMed
46.
Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu CH, Nagle R, Sagerman P, et al. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer. 2012;118(23):5848–56.
CrossRefPubMedPubMedCentral
47.
Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer. 2007;110(11):2519–27.
CrossRefPubMed
48.
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–94.
CrossRefPubMed
49.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.
CrossRefPubMed
50.
Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst. 2006;98(21):1538–46.
CrossRefPubMed
51.
Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, et al. A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014;7(5):496–504.
CrossRefPubMedPubMedCentral
52.
Kligman LH, Akin FJ, Kligman AM. Sunscreens prevent ultraviolet photocarcinogenesis. J Am Acad Dermatol. 1980;3(1):30–5.
CrossRefPubMed
53.
Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, Rush WL, et al. Neonatal sunburn and melanoma in mice. Nature. 2001;413(6853):271–2.
CrossRefPubMed
54.
Drolet BA, Connor MJ. Sunscreens and the prevention of ultraviolet radiation-induced skin cancer. J Dermatol Surg Oncol. 1992;18(7):571–6.
CrossRefPubMed
55.
Hersey P, MacDonald M, Burns C, Schibeci S, Matthews H, Wilkinson FJ. Analysis of the effect of a sunscreen agent on the suppression of natural killer cell activity induced in human subjects by radiation from solarium lamps. J Invest Dermatol. 1987;88(3):271–6.
CrossRefPubMed
56.
Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63.
CrossRefPubMed
57.
Carrera C, Puig-Butille JA, Aguilera P, Ogbah Z, Palou J, Lecha M, et al. Impact of sunscreens on preventing UVR-induced effects in nevi: in vivo study comparing protection using a physical barrier vs sunscreen. JAMA Dermatol. 2013;149(7):803–13.
CrossRefPubMed
58.
Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151(4):903–6.
CrossRefPubMed
59.
Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC. Treatment of dysplastic nevi with 5 % imiquimod cream, a pilot study. J Drugs Dermatol. 2006;5(1):56–62.
PubMed
60.
Somani N, Martinka M, Crawford RI, Dutz JP, Rivers JK. Treatment of atypical nevi with imiquimod 5 % cream. Arch Dermatol. 2007;143(3):379–85.
CrossRefPubMed
61.
Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015;527(7577):186–91.
CrossRefPubMedPubMedCentral
62.
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–8.
CrossRefPubMed
63.
Jagtap D, Rosenberg CA, Martin LW, Pettinger M, Khandekar J, Lane D, et al. Prospective analysis of association between use of statins and melanoma risk in the Women’s Health Initiative. Cancer. 2012;118(20):5124–31.
CrossRefPubMedPubMedCentral